CollPlant Biotechnologies Ltd Ordinary Shares (CLGN) Stock Price
CLGNStock
$3.63−84.48%52W
Market Cap$6.85M
P/E—
PEG Ratio—
Div yield—
Beta0.62
CLGN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)13.81%
Price vs S&P 500 (4W)-14.37%
VGM Score27.96
CLGN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q4 2025 | -$1.90 | -$2.50 | -31.58%(-$0.60) | |
| Q3 2025 | $1.55 | -$2.70 | -274.19%(-$4.25) | |
| Q2 2025 | -$1.00 | -$2.80 | -180.00%(-$1.80) | |
| Q1 2025 | -$0.40 | -$1.30 | -225.00%(-$0.90) |
CLGN Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.14
4.14
4.14
4.14
Industry Peers — Orthopedic & Prosthetic Devices(31)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth (5Y) | Gross Margin (TTM) | Operating Margin (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
CLGNCollPlant Biotechnologies Ltd Ordinary Shares | D | F | C | 17.6x | -17.3% | -147.6% | -3329.1% | $3.63 |
| ISRGIntuitive Surgical Inc. | D | B | B | 13.7x | 18.2% | 66.7% | 31.3% | $426.70 |
| EWEdwards Lifesciences Corp | D | C | B | 7.7x | 6.7% | 77.8% | 18.2% | $86.60 |
| STESTERIS plc | C | C | B | 3.6x | 13.8% | 44.4% | 18.9% | $222.66 |
| ZBHZimmer Biomet Holdings, Inc. | B | C | B | 2.1x | 3.2% | 69.9% | 14.2% | $94.98 |
| SNNSmith & Nephew plc | B | C | C | 1.9x | 6.2% | 68.2% | 12.9% | $29.06 |
| ALGNAlign Technology Inc | B | D | C | 2.5x | 10.3% | 69.0% | 13.2% | $147.31 |
| MSAMine Safety Incorporated | C | C | B | 3.5x | 6.8% | 47.6% | 21.2% | $179.05 |
| ESTAEstablishment Labs Holdings Inc. | F | A | C | 7.2x | 20.0% | 70.5% | -7.6% | $59.18 |
| ENOVEnovis Corporation | B | D | C | 0.5x | -6.0% | 61.4% | -45.1% | $19.59 |
| CDRECadre Holdings, Inc. | B | C | C | 1.6x | 8.6% | 41.8% | 10.1% | $26.38 |
About CollPlant Biotechnologies Ltd Ordinary Shares
CollPlant Biotechnologies develops regenerative and aesthetic medicine solutions using its proprietary plant-based rhCollagen technology for 3D bioprinting and tissue engineering applications. The company generates revenue through BioInk product sales, rhCollagen therapeutics for aesthetics and medical indications, and strategic partnerships. Its primary markets span the United States, Europe, Canada, and Israel, targeting opportunities in tissue repair, organ manufacturing, and medical aesthetics.